Uptake of oxaliplatin and bevacizumab for treatment of node-positive and metastatic colon cancer

Journal of Oncology Practice

Volumn 8, Issue 3, 2012, Pages 156-163

  Neugut, Alfred I ^a   Becker, Daniel J ^a   Insel, Beverly J ^a   Hershman, Dawn L ^a  

^a

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT THERAPY; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL PRACTICE; COLON CANCER; COLORECTAL CANCER; COMORBIDITY; DATA BASE; DRUG APPROVAL; DRUG USE; FACTORIAL ANALYSIS; FEMALE; FOOD AND DRUG ADMINISTRATION; GERIATRIC PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MEDICARE; MULTIVARIATE ANALYSIS; OFF LABEL DRUG USE; ONCOLOGIST; PATIENT SELECTION; PHYSICIAN; PREDICTION; SCORING SYSTEM; UNITED STATES;

EID: 84867916557     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2011.000371     Document Type: Article

References (34)

1. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004 (Pubitemid 38702845)
2. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000 (Pubitemid 30162806)
3. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004 (Pubitemid 41095086)
4. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004 (Pubitemid 38702844)
5. Wolmark N, Yothers G, O'Connell MJ, et al: A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol 27:8s, 2009 (suppl; abstr LBA4)
6. National Cancer Institute: Drug developmentandapproval. http://www.cancer.gov/cancertopics/treatment/druginformation
7. Warren JL, Harlan LC, Fahey A, et al: Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40: IV-55-61, 2002 (suppl 8)
8. Warren JL, Klabunde CN, Schrag D, et al: Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 40:IV-3-18, 2002 (suppl 8)
9. Baldwin LM, Adamache W, Klabunde CN, et al: Linking physician characteristics and medicare claims data: Issues in data availability, quality, and measurement. Med Care 40:IV-82-95, 2002 (suppl 8)
10. American Medical Association: Division of survey and data resources: Physician master file, 2007. http://www.ama-assn.org/ama/pub/about-ama/ physician-data-resources/physician-masterfile.page?
11. Du XL, Fang S, Vernon SW, et al: Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer 110:660-669, 2007 (Pubitemid 47106157)
12. Klabunde CN, Potosky AL, Legler JM, et al: Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258-1267, 2000 (Pubitemid 32007842)
13. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987 (Pubitemid 17055592)
14. Zeger SL, Liang KY, Albert PS: Models for longitudinal data: A generalized estimating equation approach. Biometrics 44:1049-1060, 1988 (Pubitemid 19026037)
15. Panageas KS, Schrag D, Russell Localio A, et al: Properties of analysis methods that account for clustering in volume: Outcome studies when the primary predictor is cluster size. Stat Med 26:2017-2035, 2007 (Pubitemid 46534090)
16. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352:476-487, 2005
17. Cassidy J: Adjuvant chemotherapy for colon cancer. Am Soc Clin Oncol Ed Book 260-263, 2005
18. Sundararajan V, Mitra N, Jacobson JS, et al: Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136:349-357, 2002 (Pubitemid 34183993)
19. Hershman D, McBride R, Jacobson JS, et al: Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 23:6639-6646, 2005 (Pubitemid 46190258)
20. Neugut AI, Matasar M, Wang X, et al: Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 24:2368-2375, 2006 (Pubitemid 46630669)
21. Du XL, Osborne C, Goodwin JS: Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 20:4636-4642, 2002 (Pubitemid 36025279)
22. Goodwin JS, Hunt WC, Key CR, et al: The effect of marital status on stage, treatment, and survival of cancer patients. JAMA 258:3125-3130, 1987 (Pubitemid 17156228)
23. Jessup JM, Stewart A, Greene FL, et al: Adjuvant chemotherapy for stage III colon cancer: Implications of race/ethnicity, age, and differentiation. JAMA 294: 2703-2711, 2005 (Pubitemid 41770099)
24. Younis T, Al-Fayea T, Virik K, et al: Adjuvant chemotherapy uptake in nonsmall cell lung cancer. J Thorac Oncol 3:1272-1278, 2008
25. Giordano SH, Duan Z, Kuo YF, et al: Impact of a scientific presentation on community treatment patterns for primary breast cancer. J Natl Cancer Inst 98: 382-388, 2006
26. Buban GM, Link BK, Doucette WR: Influences on oncologists' adoption of new agents in adjuvant chemotherapy of breast cancer. J Clin Oncol 19:954-959, 2001 (Pubitemid 32176269)
27. Booth CM, Shepherd FA, Peng Y, et al: Adoption of adjuvant chemotherapy for non-small-cell lung cancer: A population-based outcomes study. J Clin Oncol 28:3472-3478, 2010
28. Hershman DL, Buono D, Jacobson JS, et al: Surgeon characteristics and use of breast conservation surgery in women with early stage breast cancer. Ann Surg 249:828-833, 2009
29. Hodgson DC, Fuchs CS, Ayanian JZ: Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst 93:501-515, 2001 (Pubitemid 32318429)
30. Porter GA, Soskolne CL, Yakimets WW, et al: Surgeon-related factors and outcome in rectal cancer. Ann Surg 227:157-167, 1998 (Pubitemid 28087906)
31. Hershman DL, Buono D, McBride RB, et al: Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women. Cancer 115:3848-3857, 2009
32. Laetz T, Silberman G: Reimbursement policies constrain the practice of oncology. JAMA 266:2996-2999, 1991
33. Poole SG, Dooley MJ: Off-label prescribing in oncology. Support Care Cancer 12:302-305, 2004 (Pubitemid 38647853)
34. Roila F, Ballatori E, Labianca R, et al: Off-label prescription of antineoplastic drugs: An Italian prospective, observational, multicenter survey. Tumori 95:647- 651, 2009